                         SEQUENCE LISTING

<110>  Agency for Science, Technology and Research
 
<120>  ANTI-CTLA-4 ANTIBODIES

<130>  RIC/FP7253289

<140>  10201603721T
<141>  2016-05-10

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone light chain variable domain

<400>  1

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Thr Gln Gly Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Thr Leu Pro Leu 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105             


<210>  2
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 gl clone light chain variable domain

<400>  2

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Thr Gln Gly Ile Ser Ser Trp 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala Asn Thr Leu Pro Leu 
                85                  90                  95      


Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 
            100                 105             


<210>  3
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone heavy chain variable domain

<400>  3

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Thr Val Ser Ser Asn 
            20                  25                  30          


Thr Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 
        35                  40                  45              


Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly 
    50                  55                  60                  


Leu Ser Val Lys Ser Arg Met Thr Ile Asn Ala Asp Thr Ser Lys Asn 
65                  70                  75                  80  


Gln Val Ser Leu His Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 
                85                  90                  95      


Tyr Tyr Cys Ala Arg Glu Gly Ser Gly Gly Thr Leu Ile Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  4
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 gl clone heavy chain variable domain

<400>  4

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn 
            20                  25                  30          


Thr Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu 
        35                  40                  45              


Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly 
    50                  55                  60                  


Leu Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn 
65                  70                  75                  80  


Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val 
                85                  90                  95      


Tyr Tyr Cys Ala Arg Glu Gly Ser Gly Gly Thr Leu Ile Tyr Trp Gly 
            100                 105                 110         


Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone light chain variable domain 
       LC-CDR1

<400>  5

Arg Ala Thr Gln Gly Ile Ser Ser Trp Leu Ala 
1               5                   10      


<210>  6
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone light chain variable domain 
       LC-CDR2

<400>  6

Ala Ala Ser Ser Leu Gln Ser 
1               5           


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone light chain variable domain 
       LC-CDR3

<400>  7

Gln Gln Ala Asn Thr Leu Pro Leu Phe Thr 
1               5                   10  


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone heavy chain variable domain 
       LC-CDR1

<400>  8

Ser Asn Thr Ala Ala Trp Asn 
1               5           


<210>  9
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone heavy chain variable domain 
       LC-CDR2

<400>  9

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Ser Asp Tyr Gly Leu Ser Val 
1               5                   10                  15      


Lys Ser 
        


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone heavy chain variable domain 
       LC-CDR3

<400>  10

Glu Gly Ser Gly Gly Thr Leu Ile Tyr 
1               5                   


<210>  11
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone light chain variable domain

<400>  11
gacatccagt tgacccagtc tccatcttct gtgtctgcat ctgtgggaga cagagtcacc       60

atcacttgtc gggcgactca gggtataagc agctggttag cctggtatca gcagaaacca      120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatcc      180

aggttcagcg gcagtggctc tgggacagag ttcactctca ctatcagcag cctgcagcct      240

gaagattttg caacttacta ttgtcaacag gctaatactc tccccttatt cactttcggc      300

cctgggacca aagtggatat caaa                                             324


<210>  12
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 gl clone light chain variable domain

<400>  12
gacatccaga tgacccagtc tccatcttct gtgtctgcat ctgtgggaga cagagtcacc       60

atcacttgtc gggcgactca gggtataagc agctggttag cctggtatca gcagaaacca      120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatcc      180

aggttcagcg gcagtggctc tgggacagat ttcactctca ctatcagcag cctgcagcct      240

gaagattttg caacttacta ttgtcaacag gctaatactc tccccttatt cactttcggc      300

cctgggacca aagtggatat caaa                                             324


<210>  13
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 clone heavy chain variable domain

<400>  13
caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc       60

acctgcgcca tctccgggga cactgtctct agcaacactg ctgcttggaa ttggatcagg      120

cagtccccct cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat      180

agtgactatg gactatctgt gaaaagtcgg atgaccatca atgcagacac atccaagaac      240

caggtctccc tacacctgaa ctctgtaact cccgaagaca cggctgtata ttactgtgca      300

agagagggca gtggcggaac tttgatctac tggggccagg gaaccctggt caccgtctca      360

agc                                                                    363


<210>  14
<211>  363
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  anti-CTLA-4 antibody 2C8 gl clone heavy chain variable domain

<400>  14
caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc       60

acctgcgcca tctccgggga cagtgtctct agcaacactg ctgcttggaa ttggatcagg      120

cagtccccct cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat      180

agtgactatg gactatctgt gaaaagtcgg ataaccatca atccagacac atccaagaac      240

cagttctccc tacagctgaa ctctgtaact cccgaagaca cggctgtata ttactgtgca      300

agagagggca gtggcggaac tttgatctac tggggccagg gaaccctggt caccgtctca      360

agc                                                                    363


